Building upon these findings, a phase I clinical trial investigating the safety and preliminary efficacy of the BRAF inhibitor (vemurafenib) and EGFR inhibitor (cetuximab) regimen, combined with the PD-1 monoclonal antibody (camrelizumab) for BRAFV600E–mutant/MSS type metastatic colorectal cancer, is ongoing (NCT05019534). The gene discussed is BRAF; the disease is metastatic colorectal cancer.